



(11) **EP 2 844 642 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**25.12.2019 Bulletin 2019/52**

(45) Date of publication and mention  
of the grant of the patent:  
**13.11.2019 Bulletin 2019/46**

(21) Application number: **13788352.6**

(22) Date of filing: **15.03.2013**

(51) Int Cl.:  
**C07D 239/48** <sup>(2006.01)</sup> **C07D 403/12** <sup>(2006.01)</sup>  
**C07F 9/6561** <sup>(2006.01)</sup> **C07F 9/6584** <sup>(2006.01)</sup>  
**C07F 9/6512** <sup>(2006.01)</sup> **C07F 9/6521** <sup>(2006.01)</sup>  
**A61K 31/505** <sup>(2006.01)</sup> **A61K 31/506** <sup>(2006.01)</sup>  
**A61P 35/00** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2013/032713**

(87) International publication number:  
**WO 2013/169401 (14.11.2013 Gazette 2013/46)**

(54) **COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS**

VERFAHREN ZUR HEMMUNG DER ZELLPROLIFERATION BEI EFGR-VERMITTELTEM KREBS  
COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS  
PAR L'EGFR

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**  
Designated Extension States:  
**BA ME**

(30) Priority: **05.05.2012 US 201261643228 P**  
**07.11.2012 US 201261723779 P**  
**08.11.2012 US 201261724283 P**

(43) Date of publication of application:  
**11.03.2015 Bulletin 2015/11**

(73) Proprietor: **ARIAD PHARMACEUTICALS, INC.**  
**Cambridge, MA 02139-4234 (US)**

(72) Inventors:  
• **ZHU, Xiaotian**  
**Newton, MA 02465 (US)**

• **WANG, Yihan**  
**Newton, MA 02460 (US)**  
• **SHAKESPEARE, William, C.**  
**Southborough, MA 01772 (US)**  
• **HUANG, Wei-Sheng**  
**Acton, MA 01720 (US)**  
• **DALGARNO, David, C.**  
**Brookline, MA 02446 (US)**

(74) Representative: **D Young & Co LLP**  
**120 Holborn**  
**London EC1N 2DY (GB)**

(56) References cited:  
**WO-A1-2009/143389 WO-A1-2011/090760**  
**WO-A1-2012/051587 US-A1- 2011 230 494**  
**US-A1- 2012 094 999 US-A1- 2012 316 135**

**EP 2 844 642 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).